Association between lipoprotein(a) and thromboembolism in patients with non-valvular atrial fibrillation: a cross-sectional study

Table 2 Ischemic stroke risk of different lipoprotein (a) levels (mg/dL) in patients with non-valvular atrial fibrillation

Lp (a)	Events, n (%)	Crude model		Model1		Model 2		Model 3
Lp (a)	Events, n (%)	OR (95% CI)	P	OR (95% CI)	P	OR (95% CI)	P	OR (95% CI)	P
Q1 (< 7.1)	289 (7.0)	1.00		1.00		1.00		1.00
Q2 [7.1, 13.4)	335 (8.2)	1.18 (1.00, 1.39)	0.044	1.14 (0.96, 1.34)	0.126	1.15 (0.97, 1.36)	0.110	1.13 (0.95, 1.34)	0.161
Q3 [13.4, 25.4)	338 (8.3)	1.19 (1.01, 1.40)	0.038	1.14 (0.97, 1.34)	0.125	1.16 (0.98, 1.37)	0.084	1.14 (0.96, 1.35)	0.124
Q4 (≥ 25.4)	357 (8.8)	1.27 (1.08, 1.49)	0.004	1.21 (1.03, 1.42)	0.024	1.22 (1.03, 1.43)	0.021	1.23 (1.04, 1.45)	0.013
P for trend	0.007^a		0.034		0.150		0.128		0.122
Log-Lp(a)		1.25 (1.09, 1.43)	0.001	1.20 (1.05, 1.37)	0.009	1.21 (1.05, 1.39)	0.007	1.23 (1.07, 1.41)	0.004

Abbreviations: Lp(a) Lipoprotein(a), Log log-transformed, OR Odds ratio, 95% CI 95% confidence interval
Model 1: adjusted for sex, age, and ethnicity; Model 2: adjusted for CHA₂DS₂-VASc score; Model 3: adjusted for ethnicity, CHA₂DS₂-VASc score, anticoagulants, lipid-lowering medications, triglycerides, total cholesterol, high-density lipoprotein cholesterol, low-density lipoprotein cholesterol, apolipoprotein A1, apolipoprotein B, and red-cell distribution width
^aMantel-Haenszel χ² test

ISSN: 1476-511X